Survodutide vs Tripeptide-29
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideSkin & CosmeticAnti-Aging & Longevity
Tripeptide-29- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Tripeptide-29 is a pro-collagen cosmetic peptide composed of proline, hydroxyproline, and glycine — the core repeating unit of collagen. Applied topically, it signals dermal fibroblasts that collagen degradation has occurred, triggering compensatory new collagen synthesis.
- Half-Life
- ~7 days
- Not applicable (topical)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 0.01-0.1% in formulation
- Frequency
- Once weekly
- Once or twice daily
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Stimulates fibroblast collagen synthesis via damage-signal mechanism
- Reduces fine lines and improves skin smoothness
- Supports dermal matrix integrity
- Naturally bioidentical to collagen fragment sequences
- Well-tolerated in all skin types
- Synergistic with copper peptides and retinoids
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Excellent tolerability profile
- No documented significant adverse effects at cosmetic concentrations
- Rare sensitivity reactions in individuals with peptide allergies
- Stacks With
- —
- —